



# III Memorial "Alicia Pueyo" Workshop

Research on DIPG
Barcelona, February 26<sup>th</sup> 2015

#### Venue:

ABBA GARDEN HOTEL C/Santa Rosa, 33 08950 Esplugues de Llobregat (Just beside Hospital Sant Joan de Déu)

## Final Agenda

**Session 1**: The clinical challenges of current DIPG management. 8:30 AM to 9:30 AM

**1. KATHERINE E.WARREN**. Pediatric Oncology Branch, NCI. National Institute of Health. Bethesda, USA

How poised is DIPG for envisioning cure? (20')

2. MAURA MASSIMINO. Istituto Nazionale dei Tumori

Current clinical management of DIPG: Nimotuzumab plus Vinorelbine, radiation and beyond. (15')

**3. BEATE TIMMERMANN**. Westdeutsches Protonentherapiezentrum Essen Radiotherapy strategies for the management of DIPG patients. (15')

**Session 2**: First biopsy and genomics 9:30 AM to 110:45 PM

**4. MARK KIERAN.** Dana-Farber Cancer Institute and Children's Hospital Boston, USA

Genomic advances in the understanding of DIPG and its translational opportunities. The USA perspective. (30')

5. JACQUES GRILL. Institut de cancérologie Gustave Roussy.

Genomic advances in the understanding of DIPG and its translational opportunities. The European perspective. (30')

**Short Abstract Presentation 1 (Oral selection)** 

Break 1: 10:45 to 11:00 AM Coffee Break

Sponsored by:







**Session 3**: Clinical trials. How to measure progress. 11:00 to 13:30 PM

**6. DANNIS VAN VUURDEN**. VU University Medical Center Amsterdam. Survival prediction model for DIPG. International consensus?. (30')

**7.SANNA-MARIA KIVIVUORI**. Helsinki University Central Hospital Current clinical management of DIPG: anti angiogenic strategies (30')

## 8. STEVE LOWIS. University Hospital of Bristol

Development of an implantable catheter system for repeated cycles of CED in pediatric DIPG (30')

**9. MARK M. SOUWEDAINE**. Weill Medical College of Cornell University CED strategies for DIPG control. How close?. (30')

### **Short Abstract Presentation 2 (Oral selection)**

Break 2 13:30 to 14:30 PM Lunch

**Session 4**: Let's start the future.

14:30 to 16:30 PM

#### **10. CHRIS JONES**. The Institute of Cancer Research, Sutton.

Genomic advances in the understanding of DIPG and its translational opportunities: ACVR1 and beyond. (30')

**11. RINTARO HASHIZUME**. Feinberg School of Medicine. Northwestern U. Chicago

Epigenetic approaches to target DIPG (30')

#### 12. OREN BECHER. Duke Cancer Center

Genetically engineered mouse modeling of DIPG. Translational opportunities. (30')

**13. ANGEL M. CARCABOSO**. Developmental tumor Laboratory. HSJD HSJD Xenograft animal model for DIPG. (20')

**Short Abstract Presentation 3 (Oral selection)** 

Break 3: 16:30 to 16:45 PM Coffee

Sponsored by:







**Session 5**: *Immunotherapy approaches: hurdles and achievements.* 16:45 to 18:00 PM

## 14. IAN POLLACK. Children's Hospital of Pittsburgh

Immunotherapy approaches for children with DIPG: present and future developments. (30')

## 15. STEFAAN VAN GOOL. University Hospital Leuven

Oncolytic virotherapy and cellular immunotherapy against DIPG. Translational opportunities. (30')

**16. ANDRES MORALES**. Pediatric Neuro-Oncology. HSJD Barcelona. HSJD Dendritic cell vaccine protocol. (15')

## **Short Abstract Presentation 4(Oral selection)**

**Closing session**: *The families support and impulse*. 18:15 to 18:30 PM

GLORIA GARCIA (Alicia's mother).



